245 related articles for article (PubMed ID: 31421077)
1. Risk of progression in Barrett's esophagus indefinite for dysplasia: a systematic review and meta-analysis.
Krishnamoorthi R; Mohan BP; Jayaraj M; Wang KK; Katzka DA; Ross A; Adler DG; Iyer PG
Gastrointest Endosc; 2020 Jan; 91(1):3-10.e3. PubMed ID: 31421077
[TBL] [Abstract][Full Text] [Related]
2. Risk of malignant progression in Barrett's esophagus indefinite for dysplasia.
Ma M; Shroff S; Feldman M; DeMarshall M; Price C; Tierney A; Falk GW
Dis Esophagus; 2017 Mar; 30(3):1-5. PubMed ID: 28184470
[TBL] [Abstract][Full Text] [Related]
3. A Tissue Systems Pathology Test Detects Abnormalities Associated with Prevalent High-Grade Dysplasia and Esophageal Cancer in Barrett's Esophagus.
Critchley-Thorne RJ; Davison JM; Prichard JW; Reese LM; Zhang Y; Repa K; Li J; Diehl DL; Jhala NC; Ginsberg GG; DeMarshall M; Foxwell T; Jobe BA; Zaidi AH; Duits LC; Bergman JJ; Rustgi A; Falk GW
Cancer Epidemiol Biomarkers Prev; 2017 Feb; 26(2):240-248. PubMed ID: 27729357
[TBL] [Abstract][Full Text] [Related]
4. Risk of neoplastic progression in Barrett's esophagus diagnosed as indefinite for dysplasia: a nationwide cohort study.
Kestens C; Leenders M; Offerhaus GJ; van Baal JW; Siersema PD
Endoscopy; 2015 May; 47(5):409-14. PubMed ID: 25521571
[TBL] [Abstract][Full Text] [Related]
5. Risk stratification of patients with barrett's esophagus and low-grade dysplasia or indefinite for dysplasia.
Thota PN; Lee HJ; Goldblum JR; Liu X; Sanaka MR; Gohel T; Kanadiya M; Lopez R
Clin Gastroenterol Hepatol; 2015 Mar; 13(3):459-465.e1. PubMed ID: 25102445
[TBL] [Abstract][Full Text] [Related]
6. Risk for esophageal neoplasia in Barrett's esophagus patients with mucosal changes indefinite for dysplasia.
Horvath B; Singh P; Xie H; Thota PN; Allende DS; Pai RK; Patil DT; Plesec TP; Goldblum JR; Liu X
J Gastroenterol Hepatol; 2015 Feb; 30(2):262-7. PubMed ID: 25087917
[TBL] [Abstract][Full Text] [Related]
7. Patients With Barrett's Esophagus and Persistent Low-grade Dysplasia Have an Increased Risk for High-grade Dysplasia and Cancer.
Kestens C; Offerhaus GJ; van Baal JW; Siersema PD
Clin Gastroenterol Hepatol; 2016 Jul; 14(7):956-962.e1. PubMed ID: 26748222
[TBL] [Abstract][Full Text] [Related]
8. Incidence of esophageal adenocarcinoma in Barrett's esophagus with low-grade dysplasia: a systematic review and meta-analysis.
Singh S; Manickam P; Amin AV; Samala N; Schouten LJ; Iyer PG; Desai TK
Gastrointest Endosc; 2014 Jun; 79(6):897-909.e4; quiz 983.e1, 983.e3. PubMed ID: 24556051
[TBL] [Abstract][Full Text] [Related]
9. Persistent indefinite for dysplasia in Barrett's esophagus is a risk factor for dysplastic progression to low-grade dysplasia.
Henn AJ; Song KY; Gravely AA; Mesa H; Sultan S; Shaheen NJ; Shaukat A; Hanson BJ
Dis Esophagus; 2020 Sep; 33(9):. PubMed ID: 32399569
[TBL] [Abstract][Full Text] [Related]
10. Association between length of Barrett's esophagus and risk of high-grade dysplasia or adenocarcinoma in patients without dysplasia.
Anaparthy R; Gaddam S; Kanakadandi V; Alsop BR; Gupta N; Higbee AD; Wani SB; Singh M; Rastogi A; Bansal A; Cash BD; Young PE; Lieberman DA; Falk GW; Vargo JJ; Thota P; Sampliner RE; Sharma P
Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1430-6. PubMed ID: 23707463
[TBL] [Abstract][Full Text] [Related]
11. Persistent confirmed low-grade dysplasia in Barrett's esophagus is a risk factor for progression to high-grade dysplasia and adenocarcinoma in a US Veterans cohort.
Song KY; Henn AJ; Gravely AA; Mesa H; Sultan S; Shaheen NJ; Shaukat A; Hanson BJ
Dis Esophagus; 2020 Mar; 33(2):. PubMed ID: 31274147
[TBL] [Abstract][Full Text] [Related]
12. Surveillance and follow-up strategies in patients with high-grade dysplasia in Barrett's esophagus: a Dutch population-based study.
Verbeek RE; van Oijen MG; ten Kate FJ; Vleggaar FP; Schipper ME; Casparie MK; van Baal JW; Siersema PD
Am J Gastroenterol; 2012 Apr; 107(4):534-42. PubMed ID: 22270082
[TBL] [Abstract][Full Text] [Related]
13. Increasing prevalence of high-grade dysplasia and adenocarcinoma on index endoscopy in Barrett's esophagus over the past 2 decades: data from a multicenter U.S. consortium.
Desai M; Lieberman DA; Kennedy KF; Hamade N; Thota P; Parasa S; Gorrepati VS; Bansal A; Gupta N; Gaddam S; Young PE; Mathur S; Moawad FJ; Cash BD; Sampliner R; Vargo JJ; Falk GW; Sharma P
Gastrointest Endosc; 2019 Feb; 89(2):257-263.e3. PubMed ID: 30342028
[TBL] [Abstract][Full Text] [Related]
14. Progression from low-grade dysplasia to malignancy in patients with Barrett's esophagus diagnosed by two or more pathologists.
Moole H; Patel J; Ahmed Z; Duvvuri A; Vennelaganti S; Moole V; Dharmapuri S; Boddireddy R; Yedama P; Bondalapati N; Uppu A; Vennelaganti P; Puli S
World J Gastroenterol; 2016 Oct; 22(39):8831-8843. PubMed ID: 27818599
[TBL] [Abstract][Full Text] [Related]
15. Predictors for neoplastic progression in patients with Barrett's Esophagus: a prospective cohort study.
Sikkema M; Looman CW; Steyerberg EW; Kerkhof M; Kastelein F; van Dekken H; van Vuuren AJ; Bode WA; van der Valk H; Ouwendijk RJ; Giard R; Lesterhuis W; Heinhuis R; Klinkenberg EC; Meijer GA; ter Borg F; Arends JW; Kolkman JJ; van Baarlen J; de Vries RA; Mulder AH; van Tilburg AJ; Offerhaus GJ; ten Kate FJ; Kusters JG; Kuipers EJ; Siersema PD
Am J Gastroenterol; 2011 Jul; 106(7):1231-8. PubMed ID: 21577245
[TBL] [Abstract][Full Text] [Related]
16. Patients With Barrett's Esophagus and Confirmed Persistent Low-Grade Dysplasia Are at Increased Risk for Progression to Neoplasia.
Duits LC; van der Wel MJ; Cotton CC; Phoa KN; Ten Kate FJW; Seldenrijk CA; Offerhaus GJA; Visser M; Meijer SL; Mallant-Hent RC; Krishnadath KK; Pouw RE; Tijssen JGP; Shaheen NJ; Bergman JJGHM
Gastroenterology; 2017 Apr; 152(5):993-1001.e1. PubMed ID: 28012849
[TBL] [Abstract][Full Text] [Related]
17. Barrett's Registry Collaboration of academic centers in Ireland reveals high progression rate of low-grade dysplasia and low risk from nondysplastic Barrett's esophagus: report of the RIBBON network.
O'Byrne LM; Witherspoon J; Verhage RJJ; O'Brien M; Muldoon C; Ryan C; Buckley M; Murphy T; Reynolds R; Patchett S; Kay E; Azam H; Robb W; Arumugasamy M; Mathuna PM; Leyden J; Gargan S; Doherty G; Sheahan K; Collins C; Nath A; O'Sullivan J; Donohoe CL; Ravi N; O'Toole D; Reynolds JV
Dis Esophagus; 2020 Oct; 33(10):. PubMed ID: 32193532
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Radiofrequency Ablation vs. Endoscopic Surveillance for Barrett's Esophagus With Low-Grade Dysplasia: Meta-Analysis of Randomized Controlled Trials.
Wang Y; Ma B; Yang S; Li W; Li P
Front Oncol; 2022; 12():801940. PubMed ID: 35296005
[TBL] [Abstract][Full Text] [Related]
19. Development and Validation of a Model to Determine Risk of Progression of Barrett's Esophagus to Neoplasia.
Parasa S; Vennalaganti S; Gaddam S; Vennalaganti P; Young P; Gupta N; Thota P; Cash B; Mathur S; Sampliner R; Moawad F; Lieberman D; Bansal A; Kennedy KF; Vargo J; Falk G; Spaander M; Bruno M; Sharma P
Gastroenterology; 2018 Apr; 154(5):1282-1289.e2. PubMed ID: 29273452
[TBL] [Abstract][Full Text] [Related]
20. Independent Blinded Validation of a Tissue Systems Pathology Test to Predict Progression in Patients With Barrett's Esophagus.
Davison JM; Goldblum J; Grewal US; McGrath K; Fasanella K; Deitrick C; DeWard AD; Bossart EA; Hayward SL; Zhang Y; Critchley-Thorne RJ; Thota PN
Am J Gastroenterol; 2020 Jun; 115(6):843-852. PubMed ID: 32079863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
